

Newsletter 2019-03-18

AcuCort participates at the Bio-Europe Spring conference in Vienna

Mats Lindfors, CEO of AcuCort AB (Spotlight Stock Market: ACUC) will participate at the large partnering conference Bio-Europe Spring 2019 in Vienna, Austria, March 25 – 27th. Bio-Europe is a recurring and well-established forum for companies to present themselves, build networks and seek partners.

In November 2018 AcuCort participated at the Bio-Europe conference in Copenhagen, Denmark. The conference in Vienna is an excellent opportunity to follow-up on previous meeting contacts and to establish new contacts.

- During the last year, AcuCort has taken several important steps towards registration and commercialization of the company's drug candidate Dexa ODF. I look forward to the opportunities to expand AcuCort's network at the Bio-Europe Spring conference and to meet potential partners for the future commercialization of the product," says Mats Lindfors, CEO of AcuCort.

For more information, please contact

Mats Lindfors, CEO, AcuCort AB

Mobile: +46 70 790 58 15

E-mail: mats.lindfors@acucort.se

About AcuCort

AcuCort develops and commercializes Dexa ODF, a fast-dissolving oral film containing the well-known glucocorticoid - dexamethasone. Dexa ODF is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of acute allergic reactions, viral croup in children and chemotherapy-induced nausea and vomiting (CINV). The bioequivalence study that forms the basis of the application for marketing approval in Europe is carried out with positive results, which strengthens the assessment that the time until commercialization of Dexa ODF may be relatively short.

AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden.

Learn more at www.acucort.se

About Bio-Europe Spring 2019

For more information about the conference, visit

<https://ebdgroup.knect365.com/bioeurope-spring/>